The head of Novartis Innovative Drugs China confirmed!

In recent days, two more multinational pharmaceutical companies have announced major personnel changes
.
First, it is reported that after Novartis Global announced the integration of the two business divisions of pharmaceuticals and oncology into one innovative drug division, Zhang Ying, president of Novartis Pharmaceuticals (China), was appointed as the president and managing director of Innovative Drugs China.
Since June 1 effective from today
.
Second, Bayer appointed Dr.
Tara Frenkl to lead its Oncology Strategic Business Unit, effective April 25, reporting directly to Christine Roth, Head of Bayer Pharma’s Oncology Strategic Business Unit
.
Both Tara Frenkl and Christine Roth previously worked for GSK
.
Novartis' business "two-in-one" innovative drug China head confirmed In the past two years, multinational pharmaceutical companies have set off a new round of organizational restructuring, with frequent personnel changes
.
Not long ago, Novartis announced that it will integrate multiple business units to streamline the structure, promote growth and save costs
.
The adjustment mainly comes from three aspects.
First, it will integrate its pharmaceutical and oncology businesses into an innovative medicine division, which will have independent commercial organizations in the United States and internationally
.
Second, a new strategy and growth business will be created, combining corporate strategy, research and development and business development
.
The new division is designed to advance Novartis' growth strategy and provide opportunities to strengthen its pipeline
.
Third, the Technology Operations Department and the Customer and Technology Solutions Department will be merged to create a new Operations Department
.
Novartis said that through the restructuring, it expects to save $1 billion in expenses by 2024, and expects the new structure to be fully in place and operational by the end of 2022
.
On April 22, it was reported that Novartis has identified the regional heads of innovative drugs international, and Zhang Ying, president of Novartis Pharmaceuticals (China), has been appointed as the president and managing director of innovative drugs China
.
Zhang Ying has worked in many multinational pharmaceutical companies such as AstraZeneca and Pfizer.
Since joining Novartis, she has established the Novartis Specialty Drug Team and has been appointed as Novartis Pharmaceuticals COO, CPO, and President of China.

.
During Zhang Ying's tenure, Novartis China achieved double-digit growth for five consecutive years, and promoted the launch of several innovative drugs in China
.
In recent years, Novartis has achieved steady growth in performance
.
Novartis' 2021 net sales revenue will reach $51.
626 billion, a year-on-year increase of 6%
.
The sales revenue in the Chinese market was US$3.
052 billion, accounting for 6% of the global total
.
Novartis' performance was mainly driven by strong growth in products such as Cosentyx (secukinumab) and new heart failure drug Entresto (sacubitril-valsartan)
.
Secukinumab will achieve revenue of US$4.
718 billion in 2021, an increase of 18% year-on-year, and is Novartis' highest-selling product
.
Entresto (sacubitril-valsartan) performed even better, with sales reaching $3.
548 billion, an increase of 42%
.
In addition, the gene therapy Zolgensma is Novartis' fastest-growing blockbuster drug, with sales revenue reaching US$1.
351 billion in 2021, a year-on-year increase of 47%, and has been approved in more than 40 countries
.
Novartis said the streamlined organizational structure and operational setup supports Novartis' focus on pharmaceuticals to power the next phase of innovation, growth and productivity
.
In addition, for Sandoz's business, Novartis also said that it will make a decision to retain the business or split it this year
.
Prior to this, it was reported that private equity firms Blackstone Group and The Carlyle Group may join forces to acquire Sandoz, a generic drug company owned by Novartis, for $25 billion
.
A research firm said that if Sandoz were sold or split, Novartis would earn higher profits and possibly generate higher returns on capital
.
Bayer has even tapped two GSK executives to work on the prostate cancer track.
Bayer is also accelerating the adjustment of product pipelines and staffing, especially strengthening its foothold in the field of oncology, investing heavily in expanding research and development pipelines, and cooperating with a number of gene therapy companies
.
Leap plan of Bayer's investment arm to invest more than 1.
3 billion euros over the next three years
.
At the Global Media Day for Prescription Drugs in 2022, Bayer put forward the strategic goal of "strive to be among the top 10 in the world by 2030 for Bayer's oncology business"
.
At present, Bayer has launched 6 products and 10 indications in the global oncology market, with an important focus coming from the new drug Nubeqa for the treatment of prostate cancer
.
The just-appointed Dr.
Tara Frenkl will reportedly focus on developing the drug alongside Christine Roth
.
As Nubeqa's first full sales year, global sales in 2021 will reach 200 million euros
.
Bayer also raised its expected peak sales for Nubeqa to over 3 billion euros
.
However, Nubeqa will face stiff competition from rivals such as Pfizer and Astellas' Xtandi and Johnson & Johnson's Erleada
.
In China, Nubeqa has entered the national medical insurance list, and the market performance is worth looking forward to
.
Notably, Bayer's prostate cancer product matrix is ​​growing, and in addition to Nubeqa, the prostate cancer radiotherapy drug Xofigo has been approved for the treatment of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases patients with sexually transmitted diseases
.
Previously, Bayer also acquired exclusive rights to a differential alpha radionuclide therapy based on actinium-225 and a prostate-specific small molecule antigen (PSMA) targeting through the acquisition of Noria and subsidiary PSMA Therapeutics
.
How to maintain high growth in the Chinese market under the tide of global resource integration Under the tide of global resource integration of multinational pharmaceutical giants, last year, Pfizer officially replaced the background LOGO of "Blue Pill", which has been used for more than 70 years, with two blue spirals in the shape of a circle.
The new logo marks Pfizer's shift from diversification to a focus on developing prescription drugs and vaccines to prevent and treat disease
.
In March of this year, Johnson & Johnson announced that its medical device business was officially renamed as "Johnson & Johnson Medical Technology" worldwide, marking the transformation of Johnson & Johnson Medical into an innovative enterprise centered on patients and driven by business growth.

.
As an important driving force for the growth of global performance of multinational pharmaceutical companies, the potential of the Chinese market is self-evident, and China is accelerating its integration with the international market
.
In the financial reports released by multinational pharmaceutical companies in 2021, the revenue growth rates of Merck and Eli Lilly in China are as high as 60% and 41% respectively
.
In recent years, under the influence of multiple factors such as drug review reform, centralized procurement, and medical insurance negotiation, multinational pharmaceutical giants have also initiated a new round of structural adjustment, increased investment in China, focused on core therapeutic areas, and accelerated relying on innovative products.

.
Roche China has made adjustments one after another, upgraded and created a customer interaction business model "centered on the field of disease treatment"
.
In June last year, under the patient and disease-oriented trend, Roche started the road of "agile transformation" and established a "lymphoma sub-specialty innovation team", focusing on the standardization of lymphoma diagnosis and treatment in China and the survival benefits of lymphoma patients.
increase, and turn on the "ecosphere mode"
.
In December of the same year, Roche announced that it would set up two special areas in Guangdong Province and the Sichuan-Chongqing region to explore the "regional model"
.
Merck China merged the digital interaction and transformation and commercial operations divisions to form a new division of business excellence
.
MSD China also merged business operations and key account management to create a new business excellence department to accelerate the entry and listing of MSD China
.
In addition, a new data protection officer and chief transformation officer have been created
.
For multinational companies, a series of measures such as organizational structure adjustment, business line divestiture and merger, and replacement of executives have become the norm.
"Medicine Economic News" will continue to pay attention to how the Chinese market continues to adjust
.